Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394661 | PMC |
| http://dx.doi.org/10.1007/s00415-018-8860-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Classification of the mechanisms by which cardiotoxic plant poisons exert their effects.
Postgrad Med J
May 2023
The Royal London, Barts Health NHS Trust, London, UK.
Article Synopsis
- Plant-based poisoning cases are rare in emergency rooms but can happen when people mistakenly identify toxic plants as safe or use them for alternative medicine or psychoactive effects.
- Many of these toxins affect the heart by interacting with ion channels or specific receptors, leading to typical symptoms and ECG changes based on which targets are affected.
- The article introduces a new classification system for cardiotoxic plant poisons that aligns with the Vaughan Williams classification used for antiarrhythmic medications, aiming to improve diagnosis and memory recall in clinical settings.
Article Synopsis
- A study evaluated the effects of a higher dose of corticosteroids on COVID-19 patients who needed oxygen or ventilatory support, building on previous findings that low-dose corticosteroids reduced mortality in similar patients.
- The research was part of the RECOVERY trial, which randomly assigned patients to receive either higher dose corticosteroids or usual care with a lower dose, measuring 28-day mortality rates as the primary outcome.
- From May 2021 to May 2022, 1,272 patients were included, with notable participation from Asia and the UK; results showed that nearly all of the patients who received usual care also received some form of low-dose corticosteroids.
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group).
Background: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19.
Methods: RECOVERY is a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in patients admitted to hospital with COVID-19.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!